[Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].

We have studied the prophylactic effect of new derivatives of ursodeoxycholic acid (UDCA), including UDCA-N-acetylcysteine, UDCA-L-acetylcysteine, and nor-UDCA (in doses equivalent to 40 mg/kg of UDCA) on the development of experimental alcoholic steatohepatitis induced by the Lieber-DeCarli liquid ethanol-containing diet. Results demonstrated that most of the investigated compounds produced a hepatoprotective effect, improving biochemical tests and liver morphology, as manifested by decreasing steatosis intensity, activity of alkaline phosphatase and gamma-glutamyltranspeptidase, triglyceride level in blood serum and liver, and TNF alpha content. However, nor-UDCA was most effective as compared to UDCA in preventing the accumulation of triglycerides in the liver.

[Hepatoprotective and immunomodulatory effects of infliximab on experimental alcoholic steatohepatitis].

The effect of infliximab (1 and 10 mg/kg, i.p., during 10 days) on alcoholic steatohepatitis has been studied in rats fed with ethanol-containing liquid diet over 10 weeks.

[The effect of a diet with different contents of linoleic acid on the development of alcoholic liver diseases].

White rats received rations with varying content of linoleic acid (3.17 and 90 g/kg of food) during 30 days. The control rats that received food with low content of linoleic acid showed a higher content of triglycerides in the liver.